度伐利尤单抗联合奥拉帕利治疗复发性小细胞肺癌:一项II期研究结果
这项单臂II期试验入组20例复发性小细胞肺癌患者,接受度伐利尤单抗1500 mg每4周一次联合奥拉帕利300 mg每日两次治疗。19例可评估患者中客观缓解率为10.5%(2例),临床获益率21.1%(95%CI 6.1%-45.6%)。联合方案未达到预设疗效标准,肿瘤免疫表型可能与免疫检查点联合治疗反应相关。
要点
- 19例可评估患者中2例缓解,客观缓解率10.5%,未达预设疗效标准。
- 临床获益率21.1%(95%CI 6.1%-45.6%),包括确认缓解或持续稳定≥8个月。
- 治疗前肿瘤呈炎症表型者均观察到肿瘤缓解。
核心结论
- 该联合方案未达到预设的疗效标准。
- 治疗前及治疗中活检提示肿瘤免疫表型可能与SCLC对免疫检查点联合治疗的反应相关。
- 本研究中观察到的预先存在CD8阳性T细胞浸润的预测价值需在更大队列中确认。
研究设计与样本
- 单臂II期试验(NCT02484404),入组复发性SCLC患者,接受度伐利尤单抗1500 mg每4周一次联合奥拉帕利300 mg每日两次治疗。
- 主要终点为客观缓解率;相关研究包括强制采集治疗前及治疗中活检标本以定义SCLC免疫表型(荒漠型、排斥型、炎症型)。
- 共入组20例患者,中位年龄64岁,60%为铂类耐药/难治性疾病。
主要发现
- 19例可评估患者中2例观察到部分或完全缓解(10.5%),包括1例EGFR转化型SCLC。
- 4例患者(21.1%[95%CI 6.1%-45.6%])达到确认缓解或持续稳定疾病(≥8个月)的临床获益。
- 最常见的治疗相关不良事件为贫血(80%)、淋巴细胞减少(60%)和白细胞减少(50%)。
- 14例肿瘤中9例(64%)呈排斥型表型,21%呈炎症型,14%呈荒漠型。
- 治疗前肿瘤呈炎症表型者均观察到肿瘤缓解;5例基线无炎症表型的肿瘤在治疗中未观察到T细胞浸润或肿瘤浸润免疫细胞PD-L1表达增加。
局限性
- 本研究观察到的预先存在CD8阳性T细胞浸润的预测价值需在更大队列中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite high tumor mutationburden, immune checkpoint blockade has limited efficacy in SCLC. We hypothesized that poly (ADP-ribose) polymerase inhibition could render SCLC more susceptible to immune checkpoint blockade. METHODS: A single-arm, phase II trial (NCT02484404) enrolled patients with relapsed SCLC who received durvalumab, 1500 mg every 4 weeks, and olaparib, 300 mg twice a day. The primary outcome was objective response rate. Correlative studies included mandatory collection of pretreatment and during-treatment biopsy specimens, which were assessed to define SCLC immunephenotypes: desert (CD8-positive T-cell prevalence low), excluded (CD8-positive T cells in stroma immediately adjacent/within tumor), and inflamed (CD8-positive T cells in direct contact with tumor). RESULTS: A total of 20 patients were enrolled. Their median age was 64 years, and most patients (60%) had platinum-resistant/refractory disease. Of 19 evaluable patients, two were observed to have partial or complete responses (10.5%), including a patient with EGFR-transformed SCLC. Clinical benefit was observed in four patients (21.1% [95% confidence interval: 6.1%-45.6%]) with confirmed responses or prolonged stable disease (≥8 months). The most common treatment-related adverse events were anemia (80%), lymphopenia (60%), and leukopenia (50%). Nine of 14 tumors (64%) exhibited an excluded phenotype; 21% and 14% of tumors exhibited the inflamed and desert phenotypes, respectively. Tumor responses were observed in all instances in which pretreatment tumors showed an inflamed phenotype. Of the five tumors without an inflamed phenotype at baseline, no during-treatment increase in T-cell infiltration or programmed death ligand 1 expression on tumor-infiltrating immune cells was observed. CONCLUSIONS: The study combination did not meet the preset bar for efficacy. Pretreatment and during-treatment biopsy specimens suggested that tumor immune phenotypes may be relevant for SCLC responses to immune checkpoint blockade combinations. The predictive value of preexisting CD8-positive T-cell infiltrates observed in this study needs to be confirmed in larger cohorts.
引用
- Thomas A, Vilimas R, Trindade C, et al. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. J Thorac Oncol. 2019. PMID: 31063862. doi:10.1016/j.jtho.2019.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。